menu

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

3 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.

    However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.

    In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Miguel A. Escobar, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Biomarin; Kedrion Biopharma; Rani Therapeutics; Magellan Pharmaceuticals; Takeda Pharmaceutical Co, LTD; sanofi; uniQure; CSL Bering; Genentech, Inc; Novo Nordisk; and Pfizer, Inc. Serve(d) as a speaker or a member of a speakers bureau for: CSL Bering; Novo Nordisk; Pfizer, Inc; Kedrion Biopharma; Roche; and Bayer HeatlhCare, Inc. Contracted research: Takeda Pharmaceutical Co, LTD; Novo Nordisk; uniQure; sanofi; Pfizer, Inc; Opto Biologics; and Genentech, Inc. Cindy Leissinger, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Bayer HeatlhCare, Inc; CSL Bering; Catalyst Pharmaceuticals; Genentech, Inc; uniQure; sanofi; and Takeda Oncology. Contracted research: BioMarin Pharmaceutical, Inc. Guy A. Young, MD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speaker’s bureau for: Genentech, Inc; BioMarin Pharmaceutical, Inc; sanofi; Takeda Oncology; and Grifols. Consultant: BioMarin Pharmaceutical, Inc; Genentech, Inc; Spark Therapeutics; sanofi; Novo Nordisk; and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state  that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for hematologists, surgeons, pathologists/lab professionals, advanced practitioners (nurse practitioners, pharmacists, physician assistants, physical therapists), orthopedic specialists, primary care, emergency medicine, social workers, counselors, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with hemophilia A.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Evaluate currently available prophylactic therapies for hemophilia A to select the treatment best suited to the individual patient
    • Analyze currently available safety and efficacy data from clinical trials and real-world studies on bispecific antibody non–factor replacement therapy to make informed management decisions
    • Incorporate quality of life and cost data into shared decision making with patients to maximize treatment adherence
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 1/16/2023 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-21-085-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Social Workers
    As a Jointly Accredited Organization, AXIS Medical Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AXIS Medical Education maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credits.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

    Are you requesting ASCP CMLE Credit? If yes, an ASCP CMLE certificate will be emailed to you.

  • Disclaimer

    Disclaimer      
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • Method of Participation and Request for Credit:

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.

    However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.

    In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Miguel A. Escobar, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Biomarin; Kedrion Biopharma; Rani Therapeutics; Magellan Pharmaceuticals; Takeda Pharmaceutical Co, LTD; sanofi; uniQure; CSL Bering; Genentech, Inc; Novo Nordisk; and Pfizer, Inc. Serve(d) as a speaker or a member of a speakers bureau for: CSL Bering; Novo Nordisk; Pfizer, Inc; Kedrion Biopharma; Roche; and Bayer HeatlhCare, Inc. Contracted research: Takeda Pharmaceutical Co, LTD; Novo Nordisk; uniQure; sanofi; Pfizer, Inc; Opto Biologics; and Genentech, Inc. Cindy Leissinger, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Bayer HeatlhCare, Inc; CSL Bering; Catalyst Pharmaceuticals; Genentech, Inc; uniQure; sanofi; and Takeda Oncology. Contracted research: BioMarin Pharmaceutical, Inc. Guy A. Young, MD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speaker’s bureau for: Genentech, Inc; BioMarin Pharmaceutical, Inc; sanofi; Takeda Oncology; and Grifols. Consultant: BioMarin Pharmaceutical, Inc; Genentech, Inc; Spark Therapeutics; sanofi; Novo Nordisk; and Takeda Oncology.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state  that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for hematologists, surgeons, pathologists/lab professionals, advanced practitioners (nurse practitioners, pharmacists, physician assistants, physical therapists), orthopedic specialists, primary care, emergency medicine, social workers, counselors, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with hemophilia A.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Evaluate currently available prophylactic therapies for hemophilia A to select the treatment best suited to the individual patient
    • Analyze currently available safety and efficacy data from clinical trials and real-world studies on bispecific antibody non–factor replacement therapy to make informed management decisions
    • Incorporate quality of life and cost data into shared decision making with patients to maximize treatment adherence
  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 1/16/2023 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-21-085-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Social Workers
    As a Jointly Accredited Organization, AXIS Medical Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AXIS Medical Education maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credits.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

    Are you requesting ASCP CMLE Credit? If yes, an ASCP CMLE certificate will be emailed to you.

  • Disclaimer

    Disclaimer      
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • Method of Participation and Request for Credit:

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 May 2022
Webpack App